Product How it works Pricing Blog FAQ About Contact
Crispr Therapeutics AG

Crispr Therapeutics AG (NASDAQ: CRSP) revenue

Crispr Therapeutics AG reported revenue of $3.5m for fiscal 2025, 90.6% less than in fiscal 2024 ($37.3m). Since fiscal 2016 its revenue has fallen by 32.0%, an average decline of 4.2% a year.

Crispr Therapeutics AG's revenue has fallen for 2 years in a row, and its best year of the last 10 was fiscal 2021. The biggest drop was in fiscal 2022, −99.9%.

Revenue, in millions of US dollars5.2201641.020173.12018289.620190.72020915.020211.22022371.2202337.320243.52025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$3.5m−90.6%−$664.6m−18,933.6%
2024$37.3m−89.9%−$466.6m−1,250.4%
2023$371.2m+30,885.5%−$222.5m−60.0%
2022$1.2m−99.9%−$673.2m−56,190.4%
2021$915.0m+127,154.9%$373.5m40.8%
2020$0.7m−99.8%−$354.4m−49,295.5%
2019$289.6m+9,169.8%$46.7m16.1%
2018$3.1m−92.4%−$158.9m−5,087.8%
2017$41.0m+693.9%−$64.6m−157.7%
2016$5.2m—−$68.1m−1,319.3%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Crispr Therapeutics AG revenue compared with its sector

By revenue for its latest fiscal year, Crispr Therapeutics AG ranks 385th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Crispr Therapeutics AG, −90.6%.

RankCompanyRevenueRevenue growth
383rdOcugen$4.4m8.8%
384thCG Oncology$4.0m254.7%
385thCrispr Therapeutics AG$3.5m−90.6%
386thCAMP4 Therapeutics$3.5m436.5%
387thSurrozen$3.5m−67.4%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Crispr Therapeutics AG

How much revenue did Crispr Therapeutics AG make in fiscal 2025?
Crispr Therapeutics AG reported revenue of $3.5m for fiscal 2025, compared with $37.3m in fiscal 2024.
How much has the revenue of Crispr Therapeutics AG fallen?
Between fiscal 2016 and fiscal 2025 it went from $5.2m to $3.5m: 32.0% less, an average decline of 4.2% a year.
What was the best year for revenue at Crispr Therapeutics AG?
Of its last 10 fiscal years, fiscal 2021, with $915.0m.
Where does Crispr Therapeutics AG rank in its sector by revenue?
It ranks 385th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Crispr Therapeutics AG come from?
From the annual report (Form 10-K) that Crispr Therapeutics AG files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Crispr Therapeutics AG files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Crispr Therapeutics AG: the Crispr Therapeutics AG page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.